The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder.
- Author:
Young Hoon KO
1
;
Kyoung Sae NA
;
Chul Eung KIM
;
Seung Hyun KIM
;
Yang Whan JEON
;
Jung Seo YI
;
Moon Soo LEE
;
Shin Gyeom KIM
;
Hyun Ghang JEONG
;
Han Yong JUNG
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Ziprasidone; Schizophrenia; Switching; Pharmacotherapy; Triglyceride
- MeSH: Antipsychotic Agents; Body Weight; Cholesterol; Drug Therapy; Follow-Up Studies; Humans; Lipoproteins; Metabolome; Psychotic Disorders*; Schizophrenia*; Triglycerides; Waist-Hip Ratio
- From:Psychiatry Investigation 2014;11(4):459-466
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. METHODS: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit. RESULTS: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. CONCLUSION: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.
